Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC: targeted drug strategy. Principles and limitations
O. A. Koroleva, Yu. V. Dutikova, A.V. Trubnikov, et al.
Russian Chemical Bulletin (2022) Vol. 71, Iss. 11, pp. 2310-2334
Open Access | Times Cited: 20

Showing 20 citing articles:

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Binbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 6906-6921
Closed Access | Times Cited: 6
Research Progress in DNA Damage Response (DDR)-Targeting Modulators: from Hits to Clinical Candidates
Binbin Cheng, Zongbao Ding, Yun Hong, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117347-117347
Closed Access
Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons
S.M. Ibrahim, Muhammad Umer Khan, Iqra Khurram, et al.
Food Science & Nutrition (2025) Vol. 13, Iss. 2
Open Access
Analyses of Genes Critical to Tumor Survival Reveal Potential ‘Supertargets’: Focus on Transcription
Darya Chetverina, Nadezhda E. Vorobyeva, Balázs Győrffy, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 3042-3042
Open Access | Times Cited: 5
Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy
Mingming Zheng, Xiaoyu Zhang, Weijiao Chen, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 4, pp. 369-388
Closed Access | Times Cited: 1
Atox1-Cyclin D1 Loop Activity is Critical for Survival of Tumor Cells with Inactivated TP53
Oleg A. Kuchur, Sofya S. Pogodaeva, Anna V. Shcherbakova, et al.
Bioscience Reports (2024) Vol. 44, Iss. 6
Open Access | Times Cited: 1
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)
Binbin Cheng, Xian-Shi Ma, Yingxing Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116645-116645
Closed Access | Times Cited: 1
New derivatives of dehydroabiethylamine and adamantane: synthesis and activity as inhibitors of the repair enzyme TDP1
Kseniya S. Kovaleva, Оlga I. Yarovaya, Irina A. Chernyshova, et al.
Russian Chemical Bulletin (2024) Vol. 73, Iss. 6, pp. 1829-1835
Closed Access | Times Cited: 1
Molecular glue degrader for tumor treatment
Yuhan Hu, Yan Yan, Jiehao Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
Maria Giulia Nizi, Chiara Sarnari, Oriana Tabarrini
Molecules (2023) Vol. 28, Iss. 15, pp. 5849-5849
Open Access | Times Cited: 3
Steady-state kinetic analysis of reversible enzyme inhibitors: A case study on calf intestine alkaline phosphatase
Henry Brooke, Meghna Ghoshray, Archad Ibrahim, et al.
Methods in enzymology on CD-ROM/Methods in enzymology (2023), pp. 39-84
Closed Access | Times Cited: 2
Synthesis of 2-nicotinylidene triterpenoids: structure, complexation with palladium, and in vitro cytotoxic activity
M. S. Denisov, Daria V. Eroshenko
Russian Chemical Bulletin (2023) Vol. 72, Iss. 9, pp. 2206-2214
Closed Access | Times Cited: 2
Atox1-Cyclin D1 Loop Activity is Critical for Survival of Tumor Cells with Inactivated TP53
Oleg A. Kuchur, Sofya S. Pogodaeva, Anna V. Shcherbakova, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
Lin Ma, Xin Han
Elsevier eBooks (2024), pp. 357-378
Closed Access
The Hippo pathway as an antitumor target: time to focus on
Olga Koroleva, Alexander V. Kurkin, Аlexander А. Shtil
Expert Opinion on Investigational Drugs (2024), pp. 1-9
Closed Access
Revolutionizing lung cancer treatment: Introducing PROTAC therapy as a novel paradigm in targeted therapeutics
Atharva A. Mahajan, Gauri Panzade, Tiyasa Bhuniya, et al.
Current Problems in Cancer (2024) Vol. 54, pp. 101172-101172
Closed Access
Recombinant protein production for structural and kinetic studies: A case study using M. tuberculosis α-methylacyl-CoA racemase (MCR)
Otsile O. Mojanaga, K. Ravi Acharya, Matthew D. Lloyd
Methods in enzymology on CD-ROM/Methods in enzymology (2023), pp. 1-37
Closed Access | Times Cited: 1
Simple and Efficient Synthesis of Piperidine-2,6-Diones
Yuehua Liu, Zhang-Qin Xue, Kai-Wen Yang, et al.
(2023)
Closed Access
Page 1

Scroll to top